Compile Data Set for Download or QSAR
maximum 50k data
Found 2260 with Last Name = 'lorthiois' and Initial = 'e'
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542738(CHEMBL4637027)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542741(CHEMBL4647950)
Affinity DataIC50: <0.700nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542731(CHEMBL4642845)
Affinity DataIC50: <0.700nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542731(CHEMBL4642845)
Affinity DataIC50:  1nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50400274(CHEMBL2180765 | US9085555, 373)
Affinity DataIC50:  1nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542738(CHEMBL4637027)
Affinity DataIC50:  1nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542724(CHEMBL4636415)
Affinity DataIC50:  2nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50400273(CHEMBL2180764 | US9085555, 375)
Affinity DataIC50:  2nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542740(CHEMBL4646398)
Affinity DataIC50:  2nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542740(CHEMBL4646398)
Affinity DataIC50:  2nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50524347(CHEMBL4535197)
Affinity DataIC50:  3nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM170738(US9085555, 166)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542723(CHEMBL4643449)
Affinity DataIC50:  3nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542728(CHEMBL4635912)
Affinity DataIC50:  3nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542733(CHEMBL4646141)
Affinity DataIC50:  3nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542723(CHEMBL4643449)
Affinity DataIC50:  3nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50400275(CHEMBL2180766 | US9085555, 127)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetRenin(Homo sapiens (Human))
Novartis Pharma

Curated by ChEMBL
LigandPNGBDBM50066269(CHEMBL3401541)
Affinity DataIC50:  3nMAssay Description:Inhibition of recombinant human renin by fluorescence based FRET assay in presence of plasmaMore data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM254483(US9468661, 61)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM254486(US9468661, 64)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM254498(US9468661, 109 | US9468661, 76)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM171305(US9085555, 735)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM171311(US9085555, 741 | US9085555, 757)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM171262(US9085555, 692)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM171267(US9085555, 697)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM170864(US9085555, 292)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM170890(US9085555, 318)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM170943(US9085555, 371)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM170945(US9085555, 374)
Affinity DataIC50:  3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A(Homo sapiens (Human))
Pfizer

Curated by ChEMBL
LigandPNGBDBM50151638(8''-chloro-5''-(5-hydroxy-1,2,4-oxadiazol-3-ylmeth...)
Affinity DataIC50:  3.5nMAssay Description:Inhibition of human PDE7A1 expressed in baculovirus infected Sf9 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A(Homo sapiens (Human))
Pfizer

Curated by ChEMBL
LigandPNGBDBM50151562(7-{5-[(Z)-Cyclohexylimino]-4-methyl-4,5-dihydro-[1...)
Affinity DataIC50:  3.90nMAssay Description:Inhibition of human Phosphodiesterase 7A1 expressed in baculovirus infected Sf9 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGTPase KRas(Homo sapiens (Human))TBA
LigandPNGBDBM608937(1-(6-{(4M)-4-(5-Chloro-6- methyl-1H-indazol-4-yl)-...)
Affinity DataIC50:  4nMAssay Description:Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 6 hrs by MSD assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM170701(US9085555, 129)
Affinity DataIC50:  4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542725(CHEMBL4637683)
Affinity DataIC50:  4nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542730(CHEMBL4647909)
Affinity DataIC50:  4nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A(Homo sapiens (Human))
Pfizer

Curated by ChEMBL
LigandPNGBDBM50151635(8''-chloro-5''-(1H-1,2,3,4-tetraazol-5-ylmethoxy)s...)
Affinity DataIC50:  4nMAssay Description:Inhibition of human PDE7A1 expressed in baculovirus infected Sf9 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM254471(US9468661, 49)
Affinity DataIC50:  4nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM254475(US9468661, 53)
Affinity DataIC50:  4nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM254488(US9468661, 66)
Affinity DataIC50:  4nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM171304(US9085555, 734)
Affinity DataIC50:  4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM171314(US9085555, 744)
Affinity DataIC50:  4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM171318(US9085555, 748)
Affinity DataIC50:  4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM171319(US9085555, 749)
Affinity DataIC50:  4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM171334(US9085555, 764)
Affinity DataIC50:  4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM170872(US9085555, 300)
Affinity DataIC50:  4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM170878(US9085555, 306)
Affinity DataIC50:  4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM170953(US9085555, 383)
Affinity DataIC50:  4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50542724(CHEMBL4636415)
Affinity DataIC50:  4nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50462108(CHEMBL4246585)
Affinity DataIC50:  5nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetComplement factor D(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM254528(US9468661, 106)
Affinity DataIC50:  5nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 2260 total ) | Next | Last >>
Jump to: